ArticleFrontiers in public health2025
Global burden of plastic-surgery-related conditions, 1990-2021: a composition-aware analysis with projections to 2050.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Mechano-Genomic Frontier: Orchestrating Nuclear Deformation for Craniomaxillofacial Bone Regeneration.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Plastic surgery-related diseases impose a substantial and growing burden on global health systems, yet comprehensive estimates of their temporal trends and future projections remain scarce. This study aims to quantify the global, regional, and national burden of 12 plastic surgery-relevant conditions from 1990 to 2021 and to forecast their trajectories through 2050. Method: Data were extracted from the Global Burden of Disease Study 2021. We analyzed age-standardized incidence rate (ASIR), prevalence rate (ASPR), death rate (ASDR), and disability-adjusted life years (DALYs) across 204 countries and territories. Estimated annual percentage changes (EAPCs) were calculated to evaluate temporal trends, and a Bayesian age-period-cohort (BAPC) model was employed to project disease burden to 2050. Socio-demographic disparities were assessed using SDI-based stratification and Spearman correlation. Findings: Globally, incidence was compositionally dominated by pyoderma (about 90% in 1990-2021). Incident cases increased from 508.18 million (95% UI 489.85-527.22) in 1990 to 902.35 million (95% UI 871.47-934.10) in 2021, with an ASIR increasing from 9,611.94 to 11,560.66 per 100,000 population. In contrast, the ASPR declined from 2,862.67 to 2,207.26 per 100,000, and age-standardized mortality and DALYs rates also fell. The burden rose steeply with age: adults aged ≥60 years consistently exhibited the highest age-specific rates, and the absolute burden progressively shifted toward older populations. High-SDI regions had lower age-standardized mortality and DALYs rates than low-SDI regions, despite occasionally higher prevalence consistent with improved survival. By 2050, the absolute burden is projected to grow with population aging, while most age-standardized rates continue to decline. Interpretation: Aggregate incidence increases were driven mainly by pyoderma. Surgically relevant burdens concentrated in oncologic and burn/trauma cohorts; hence service implications should be anchored to these metrics rather than incidence. By 2050, incidence continues to rise largely from infections, while DALYs trajectories in surgically managed subgroups diverge by SDI-supporting targeted prevention, context-specific capacity strengthening, and integrated rehabilitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.